Our results show that setmelanotide (MC4R agonist) is associated with significant weight loss, body measurement, and hunger improvements in individuals who undergo treatment for obesity, and it is considered a safe drug with manageable adverse effects. The gene discussed is MC4R; the disease is Obesity.